Thymic Cancer
12
3
4
4
Key Insights
Highlights
Success Rate
57% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
25.0%
3 terminated out of 12 trials
57.1%
-29.4% vs benchmark
0%
0 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (12)
PT-112 in Subjects With Thymoma and Thymic Carcinoma
Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Molecular Analysis and Treatment Options of Thymic Malignancies
Hypofractionated Radiotherapy for Thymic Epithelial Tumors
Cardiac MRI Biomarker Testing (GCC 1618)
Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies
A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor
Genetic Evaluation of Families With Endocrine Cancers
Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors
Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity
A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer